Harmony Biosciences Reports Preliminary Q2 WAKIX Sales Of ~$261M, Up 30% YoY; Appoints Stephen Mollichella As Interim CFO
Harmony Biosciences Holdings, Inc. (NASDAQ: HRMY ) today announced preliminary, unaudited second quarter 2026 net product revenue for WAKIX® (pitolisant) of approximately $261 million, representing a new quarterly revenue record for the Company and growth of 30% year over year and 21% growth for Q2 over Q1. These resul